Your browser doesn't support javascript.
loading
H1FOO-DD promotes efficiency and uniformity in reprogramming to naive pluripotency.
Kunitomi, Akira; Hirohata, Ryoko; Osawa, Mitsujiro; Washizu, Kaho; Arreola, Vanessa; Saiki, Norikazu; Kato, Tomoaki M; Nomura, Masaki; Kunitomi, Haruko; Ohkame, Tokiko; Ohkame, Yusuke; Kawaguchi, Jitsutaro; Hara, Hiroto; Kusano, Kohji; Yamamoto, Takuya; Takashima, Yasuhiro; Tohyama, Shugo; Yuasa, Shinsuke; Fukuda, Keiichi; Takasu, Naoko; Yamanaka, Shinya.
Afiliação
  • Kunitomi A; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 606-8507, Japan; Gladstone Institute of Cardiovascular Disease, San Francisco, CA 94158, USA. Electronic address: akira.kunitomi@gladstone.ucsf.edu.
  • Hirohata R; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 606-8507, Japan; CiRA Foundation, Kyoto 606-8397, Japan.
  • Osawa M; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 606-8507, Japan.
  • Washizu K; Gladstone Institute of Cardiovascular Disease, San Francisco, CA 94158, USA.
  • Arreola V; Gladstone Institute of Cardiovascular Disease, San Francisco, CA 94158, USA.
  • Saiki N; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 606-8507, Japan.
  • Kato TM; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 606-8507, Japan; CiRA Foundation, Kyoto 606-8397, Japan.
  • Nomura M; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 606-8507, Japan; CiRA Foundation, Kyoto 606-8397, Japan.
  • Kunitomi H; Gladstone Institute of Cardiovascular Disease, San Francisco, CA 94158, USA.
  • Ohkame T; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 606-8507, Japan.
  • Ohkame Y; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 606-8507, Japan.
  • Kawaguchi J; ID Pharma Co., Ltd, Ibaraki 300-2611, Japan.
  • Hara H; ID Pharma Co., Ltd, Ibaraki 300-2611, Japan.
  • Kusano K; ID Pharma Co., Ltd, Ibaraki 300-2611, Japan.
  • Yamamoto T; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 606-8507, Japan; Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto 606-8501, Japan; Medical-risk Avoidance Based on iPS Cells Team, RIKEN Center for Advanced Intelligence Project (AIP),
  • Takashima Y; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 606-8507, Japan.
  • Tohyama S; Department of Cardiology, Keio University School of Medicine, Tokyo 160-8582, Japan.
  • Yuasa S; Department of Cardiology, Keio University School of Medicine, Tokyo 160-8582, Japan.
  • Fukuda K; Department of Cardiology, Keio University School of Medicine, Tokyo 160-8582, Japan.
  • Takasu N; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 606-8507, Japan; CiRA Foundation, Kyoto 606-8397, Japan.
  • Yamanaka S; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto 606-8507, Japan; Gladstone Institute of Cardiovascular Disease, San Francisco, CA 94158, USA; CiRA Foundation, Kyoto 606-8397, Japan; Department of Anatomy, University of California, San Francisco, San Francisco, CA 94143,
Stem Cell Reports ; 19(5): 710-728, 2024 May 14.
Article em En | MEDLINE | ID: mdl-38701780
ABSTRACT
Heterogeneity among both primed and naive pluripotent stem cell lines remains a major unresolved problem. Here we show that expressing the maternal-specific linker histone H1FOO fused to a destabilizing domain (H1FOO-DD), together with OCT4, SOX2, KLF4, and LMYC, in human somatic cells improves the quality of reprogramming to both primed and naive pluripotency. H1FOO-DD expression was associated with altered chromatin accessibility around pluripotency genes and with suppression of the innate immune response. Notably, H1FOO-DD generates naive induced pluripotent stem cells with lower variation in transcriptome and methylome among clones and a more uniform and superior differentiation potency. Furthermore, we elucidated that upregulation of FKBP1A, driven by these five factors, plays a key role in H1FOO-DD-mediated reprogramming.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article